BioAge Labs, Inc. (BIOA) company profile
Close on Nov 17, 2026Market cap $234.07MP/E –Yield –
About BioAge Labs
Pharmaceutical Preparations, SIC 2834
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for chronic metabolic diseases by targeting human aging biology. The company leverages a proprietary computational platform built on longitudinal human datasets and biobanked samples to identify molecular drivers of longevity and healthspan. Its lead product candidate, BGE-102, is an orally administered, brain-penetrant small-molecule NLRP3 inhibitor under development for cardiometabolic indications, particularly cardiovascular risk reduction in patients with obesity, and ophthalmology indications including diabetic macular edema. BioAge is also advancing apelin receptor agonists for obesity as well as earlier-stage discovery programs in collaboration with major pharmaceutical partners.
The company operates primarily through research and clinical trial collaborations, partnering on discovery and pipeline programs with firms such as Eli Lilly and Company, Novartis Pharma AG, and JiKang Therapeutics. BioAge conducts its clinical activities in clinical trial units and maintains discovery collaborations with academic institutions such as the University of Bonn. The company is co-founded and led by an executive management team based in North America.
Summary of the business section of BioAge Labs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioAge Labs, Inc.
- Headquarters
- Emeryville, CA
- Address
- 5885 Hollis Street, Suite 370 94608
- Phone
- (510) 806-1445
- Website
- bioagelabs.com
- Employees
- 62, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, California
Stock & identifiers
- Ticker
- BIOA
- Exchange
- Nasdaq
- IPO date
- Sep 26, 2024
- Shares outstanding
- 46M, Jul 31, 2026
- Public float
- $112.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1709941
- CUSIP
- 09077V100
- ISIN
- US09077V1008
- FIGI
- BBG00HBTB0M9
- Share class FIGI
- BBG00HBTB0N8
- LEI
- 529900NG0C40250Z7875
- EIN
- 47-4721157
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric Morgen | Chief Operating Officer, Director | 67,225 |
| Kristen Fortney | Chief Executive Officer, Director | 976,949 |
| Shane Barton | Principal Accounting Officer | 4,290 |
| Dov A. Goldstein Md | Chief Financial Officer | 36,575 |
| Paul D. Rubin | Chief Medical Officer | 0 |
| James Healy | Director | 2,304,901 |
| Jean Pierre Garnier | Director | – |
| Vijay Satyanand Pande | Director | 3,233,170 |
| Patrick G. Enright | Director | 1,710,589 |
| Michael H. Davidson | Director | – |
| Rekha Hemrajani | Director | 3,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Kristen Fortney Chief Executive Officer and President | $600.00K | $1.94M | $330.00K | $15.20K | $2.89M | -76% |
| Eric Morgen Chief Operating Officer | $499.60K | $732.60K | $199.84K | $15.20K | $1.45M | -41% |
| Paul Rubin Chief Medical Officer | $520.20K | $732.60K | $208.08K | $15.20K | $1.48M | -23% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 26, 2024
- Offer price
- $18.00
- Securities offered
- 11,000,000
- Gross proceeds
- $198.00M
- Exchange
- Nasdaq
- First trading day
- Sep 26, 2024
- First-day close
- $18.31+1.7%
- Lock-up ends (est.)
- Mar 25, 2025
“The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 62 employees, 60 of whom were full-time and 44 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 26, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 18, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?